Breaking News Instant updates and real-time market news.

CNCE

Concert Pharmaceuticals

$7.51

0.34 (4.74%)

07:01
12/02/19
12/02
07:01
12/02/19
07:01

Concert Pharmaceuticals initiates CTP-692 Phase 2 trial in schizophrenia

Concert Pharmaceuticals announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia. CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMDA receptor. NMDA is believed to play a key role in schizophrenia. The Phase 2 trial is designed to evaluate the safety and efficacy of three different doses of CTP-692, compared with placebo, in patients with schizophrenia who are stable on an antipsychotic medication. The company expects to report topline Phase 2 data by year end 2020.

CNCE Concert Pharmaceuticals
$7.51

0.34 (4.74%)

09/30/19
MZHO
09/30/19
NO CHANGE
Target $18
MZHO
Buy
Concert Pharmaceuticals price target lowered to $18 from $29 at Mizuho
Mizuho analyst Difei Yang lowered her price target for Concert Pharmaceuticals to $18 from $29 after the company's partner Avanir on Friday reported negative top-line results from the second Phase 3 study of AVP-786 for the treatment of moderate-to-severe Alzheimer's agitation. The analyst no longer takes into account the AVP-786 program into Concert's valuation. However, she continues to believe Concert's CTP-543 has the potential of being best in case for treating Alopecia Areata, and she notes the company has about $6 per share in cash. Yang reiterates a Buy rating on Concert Pharmaceuticals.
09/30/19
RHCO
09/30/19
NO CHANGE
Target $20
RHCO
Buy
Concert Pharmaceuticals price target lowered to $20 from $30 at SunTrust
SunTrust analyst Joon Lee lowered his price target on Concert Pharmaceuticals to $20 after the company's partner Avanir disclosed negative top-line results from the second Phase 3 study of AVP-786 for the treatment of moderate-to-severe Alzheimer's agitation. The analyst is removing the Alzheimer's agitation potential from his valuation model but maintains his Buy rating on the stock, citing the company's "best-in-class" alopecia areata data for CTP-543 and the expected start of phase 2 trial of its CTP-692 in Q4 of this year.
10/02/19
MZHO
10/02/19
NO CHANGE
Target $18
MZHO
Buy
Concert Pharmaceuticals shares offer 'significant value,' says Mizuho
Concert Pharmaceuticals shares have continued to sell off following last week's negative AVP-786 data and currently trade near the company's cash value of $5, Mizuho analyst Difei Yang tells investors in a research note. The analyst, however, continues to see "significant value" in Concert's clinical pipeline. CTP-543 remains a key value driver, and earlier-stage asset CTP-692, for the adjunctive treatment of schizophrenia, is set to enter Phase 2 in Q4 and offers additional potential upside, says Yang. The analyst reiterates a Buy rating on Concert Pharmaceuticals.
10/03/19
HCWC
10/03/19
NO CHANGE
Target $25
HCWC
Buy
Concert selloff brings attractive entry point, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Concert Pharmaceuticals to $25 from $29 following the miss of the second Phase 3 clinical study of AVP-786 for the treatment of moderate-to-severe agitation in patients with Alzheimer's disease. However, even in the absence of this partnered asset, Concert's two clinical programs, namely CTP-543 for alopecia areata and CTP-692 for schizophrenia, are sufficient to drive the fundamental value of the company, Fein tells investors in a research note. As such, he thinks the recent stock pullback may create an attractive entry point for investors to capture the value of these two programs. The analyst reiterates a Buy rating on Concert Pharmaceuticals.

TODAY'S FREE FLY STORIES

08:10
12/06/19
12/06
08:10
12/06/19
08:10
Conference/Events
The 7th OPEC and non-OPEC Ministerial Meeting will be held on December 6 »

Following the meeting at…

08:10
12/06/19
12/06
08:10
12/06/19
08:10
General news
US. November employment preview: »

US. November employment…

MEDIF

Medipharm Labs

$0.00

(0.00%)

08:09
12/06/19
12/06
08:09
12/06/19
08:09
Hot Stocks
Medipharm Labs Australia granted state licenses for cannabis substances »

MediPharm Labs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$12.99

-0.14 (-1.07%)

08:09
12/06/19
12/06
08:09
12/06/19
08:09
Initiation
Magenta Therapeutics initiated  »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

THS

TreeHouse

$50.86

0.155 (0.31%)

08:08
12/06/19
12/06
08:08
12/06/19
08:08
Conference/Events
TreeHouse to host investor meeting »

Investor breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PSMT

PriceSmart

$74.03

1.095 (1.50%)

08:08
12/06/19
12/06
08:08
12/06/19
08:08
Hot Stocks
PriceSmart opens new warehouse club in Guatemala City, Guatemala »

PriceSmart announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$74.03

1.095 (1.50%)

08:07
12/06/19
12/06
08:07
12/06/19
08:07
Hot Stocks
PriceSmart reports November net merchandise sales up 7.5% to $278.3M »

PriceSmart announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTOS

Kratos Defense

$17.20

0.05 (0.29%)

08:06
12/06/19
12/06
08:06
12/06/19
08:06
Hot Stocks
Kratos awarded $39M sole-source contract for RF signal communication services »

Kratos Defense &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JILL

J.Jill

$1.22

-0.49 (-28.66%)

08:06
12/06/19
12/06
08:06
12/06/19
08:06
Downgrade
J.Jill rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$38.17

0.33 (0.87%)

08:05
12/06/19
12/06
08:05
12/06/19
08:05
Hot Stocks
Azul reports November traffic up 30.6%, capacity up 32.5% »

Load factor was 82.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGP

Ferrellgas Partners

$0.57

-0.024 (-4.07%)

08:04
12/06/19
12/06
08:04
12/06/19
08:04
Earnings
Ferrellgas Partners reports Q1 EPS (46c), one est. (35c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SATS

EchoStar

$39.76

0.36 (0.91%)

08:03
12/06/19
12/06
08:03
12/06/19
08:03
Hot Stocks
Yahsat and Hughes launch satellite services joint venture in Brazil »

Hughes Network Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHAT

Blue Hat Interactive

$2.72

-0.01 (-0.37%)

08:02
12/06/19
12/06
08:02
12/06/19
08:02
Hot Stocks
Blue Hat signs LOI to acquire controlling interest in Fuzhou Csfctech Co. »

Blue Hat Interactive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOME

At Home Group

$5.48

-3.07 (-35.91%)

08:02
12/06/19
12/06
08:02
12/06/19
08:02
Downgrade
At Home Group rating change  »

At Home Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$16.62

0.065 (0.39%)

08:01
12/06/19
12/06
08:01
12/06/19
08:01
Recommendations
Yext analyst commentary  »

Yext price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$106.80

-0.48 (-0.45%)

08:01
12/06/19
12/06
08:01
12/06/19
08:01
Hot Stocks
Post Holdings announces new $400M share repurchase authorization »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIN

Albany International

$81.66

-1.04 (-1.26%)

, EADSY

Airbus

$0.00

(0.00%)

08:01
12/06/19
12/06
08:01
12/06/19
08:01
Hot Stocks
Albany International subsidiary signs two-year research agreement with Airbus »

Albany International…

AIN

Albany International

$81.66

-1.04 (-1.26%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$119.18

-2.64 (-2.17%)

08:01
12/06/19
12/06
08:01
12/06/19
08:01
Recommendations
Okta analyst commentary  »

Okta price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ENB

Enbridge

$38.50

0.235 (0.61%)

08:00
12/06/19
12/06
08:00
12/06/19
08:00
Conference/Events
Enbridge to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PD

PagerDuty

$24.99

-0.66 (-2.57%)

08:00
12/06/19
12/06
08:00
12/06/19
08:00
Recommendations
PagerDuty analyst commentary  »

PagerDuty price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRXC

TransEnterix

$0.19

-0.0003 (-0.16%)

07:59
12/06/19
12/06
07:59
12/06/19
07:59
Conference/Events
TransEnterix to hold a webcast »

Management hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 18

    Dec

TDOC

Teladoc

$79.34

-0.71 (-0.89%)

07:57
12/06/19
12/06
07:57
12/06/19
07:57
Downgrade
Teladoc rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

07:57
12/06/19
12/06
07:57
12/06/19
07:57
Recommendations
Zoom Video analyst commentary  »

JPMorgan sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

YEXT

Yext

$16.62

0.065 (0.39%)

07:55
12/06/19
12/06
07:55
12/06/19
07:55
Recommendations
Yext analyst commentary  »

Yext price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDAQ

Nasdaq

$104.68

-0.49 (-0.47%)

07:55
12/06/19
12/06
07:55
12/06/19
07:55
Conference/Events
House Financial Services Committee to hold a hearing »

The Task Force on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.